Total Voting Rights and Capital
In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following:
The Company's issued share capital as at 30 August 2019 consisted of 5,382,055,713 shares of 25 pence each ('Ordinary Shares'), of which 393,505,950 Ordinary Shares were held in Treasury.
Therefore, the total number of voting rights in the Company is 4,988,549,763. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
V A Whyte
2 September 2019
|London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.|
|©London Stock Exchange plc. All rights reserved|